Protagonist Therapeutics (PTGX)

Executive Summary

Protagonist Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary peptide-based platform to develop new chemical entities for diseases with high unmet need. Its lead asset, rusfertide (PTG-300), a hepcidin mimetic, has demonstrated promising Phase 2 data in polycythemia vera (PV) and hereditary hemochromatosis, with potential to become a best-in-class therapy for PV by reducing phlebotomy dependence. The company is also advancing PN-881, an oral IL-23 receptor antagonist, currently in Phase 1 healthy volunteer studies, targeting inflammatory bowel disease and other autoimmune conditions. With a robust pipeline and a market capitalization around $6.3 billion, Protagonist is positioned to address significant markets, though it faces typical clinical and regulatory risks. Near-term focus remains on advancing rusfertide into pivotal trials and generating proof-of-concept data for PN-881.

Upcoming Catalysts (preview)

• Q3 2026PN-881 Phase 1 healthy volunteer data readout70% success
• H2 2026Rusfertide (PTG-300) Phase 3 initiation in polycythemia vera80% success